Patient Gateway

RSS Feed

TRI-611, a selective, brain-penetrant molecular glue degrader of ALK

New Non-Small Cell Lung Cancer Study Results from Medical University of Gdansk Described [Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related...

Real-World ALK TKI Outcomes in Metastatic NSCLC

Advanced ALK–EML4 fusion–positive non-small cell lung cancer with intraspinal metastases: a case report

China Clinical Trial: Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences) Registers Clinical Trial to Study Lorlatinib plus Sacituzumab Tirumotecan with Peripheral ctDNA Guidance as...

Adjuvant Crizotinib Fails in Resected ALK-Positive NSCLC: What E4512 Tells Us About Targeted Therapy in Early Disease

Adjuvant Crizotinib Fails in Resected ALK-Positive NSCLC: What E4512 Tells Us About Targeted Therapy in Early Disease

Minimal residual disease guides postoperative therapy in a patient with ALK-rearranged adenocarcinoma: a case report

ALK-fusion-positive non-small cell lung cancer concomitant with 5q deletion myelodysplastic syndrome: a case report

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.